Regulatory Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy Pharmaceutical Business ReviewThe application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility.RegulatoryOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaceutical Business Review The application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly doubles down on in vivo with $7bn Kelonia buyoutNext: FDA kicks off review of Roche’s Gazyva for wider lupus use Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
